Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 501–600 of 3,704
Olsen, N. J., Østergaard, J. N., Bjerregaard, L. G., Høy, T. V., Kierkegaard, L., Michaelsen, K. F., Sørensen, T. I. A., Grønbæk, M. K., Bruun, J. M., & Heitmann, B. L. (2024) · Obesity Reviews · doi:10.1111/obr.13641 · Cited by 30
Grosicki, G. J., Dhurandhar, N. V., Unick, J. L., Arent, S. M., Thomas, J. G., Lofton, H., Shepherd, M. C., Kiel, J., Coleman, C., & Jonnalagadda, S. S. (2024) · Current Developments in Nutrition · doi:10.1016/j.cdnut.2024.104486 · Cited by 31
Jensen, T. L., Brønden, A., Karstoft, K., Sonne, D. P., & Christensen, M. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s419304 · Cited by 36
“26,27 The SURPASS clinical trial program included only participants with T2D and had mean change in HbA 1C as the primary endpoint, whereas weight loss was reported as a secondary outcome.”
BackgroundMethodInfluentialEffect of tirzepatide on body fat distribution pattern in people with type 2 diabetes
Cariou, B., Linge, J., Neeland, I. J., Leinhard, O. D., Petersson, M., Landó, L. F., Bray, R., & Rodríguez, Á. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15566 · Cited by 43
Puengel, T., & Tacke, F. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2374463 · Cited by 34
Sanchez, R. A., Coca, A., Molina, D. I., Alcocer, L. A., Aristizábal, D., Barbosa, E. C. D., Brandão, A. A., Diaz-Velazco, M. E., Hernández-Hernández, R., López-Jaramillo, P. A., et al. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003899 · Cited by 52
Rivera Gutierrez, R., Tama, E., Bechenati, D., Castañeda Hernandez, R., Bennett, P. K., McNally, A. W., Fansa, S., Anazco, D., Acosta, A., & Hurtado Andrade, M. D. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.07.006 · Cited by 31
Alkhouri, N., Charlton, M., Gray, M. E., & Noureddin, M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473062 · Cited by 34
“Body weight loss with 10 mg and 15 mg weekly doses over 72 weeks ranged from 12.8–20.9% in SURMOUNT-1 and SURMOUNT-2, while in SURMOUNT-3, tirzepatide demonstrated a further 18.4% weight loss following successful life-style intervention [167–169].”
InfluentialGLP-1 Receptor Agonists in Pediatric and Adolescent Obesity
Stefater‐Richards, M. A., Jhe, G., & Zhang, Y. J. (2025) · PEDIATRICS · doi:10.1542/peds.2024-068119 · Cited by 43
Furth, S. L., Colhoun, H. M., Kanbay, M., Kukla, A., Lim, L., MacLaughlin, H. L., Navaneethan, S. D., Shroff, R. C., Stenvinkel, P., Cheung, M., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.09.019 · Cited by 55
Obesity and Cancer: A Translational Science Review
Shen, S., Brown, K. A., Green, A. K., & Iyengar, N. M. (2026) · JAMA · doi:10.1001/jama.2026.1114 · Cited by 47
Herbozo, S., Brown, K. L., Burke, N. L., & LaRose, J. G. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00493-5 · Cited by 36
Gastaldi, G., Lucchini, B., Thalmann, S., Alder, S., Laimer, M. W., Brändle, M., Wiesli, P., Lehmann, R., & Working group of the SGED/SSED (2023) · Swiss Medical Weekly · doi:10.57187/smw.2023.40060 · Cited by 38
“If physicians have a focus on weight management, particularly in younger patients, to reduce obesity early, many diseases associated with obesity, including diabetes, could be prevented [22, 23, 28].”
BackgroundInfluential360-Degree Perspectives on Obesity
Cuciureanu, M. D., Caratașu, C.-C., Gabrielian, L., Frăsinariu, O. E., Checheriță, L. E., Trandafir, L. M., Stanciu, G. D., Szilagyi, A., Pogonea, I., Bordeianu, G., et al. (2023) · Medicina · doi:10.3390/medicina59061119 · Cited by 37
Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment
Sannidhi, D., Abeles, R., Andrew, W., Bonnet, J. P., Vitale, K., Niranjan, V., Gulati, M., Pauly, K., Moran, R., Alexander, L., et al. (2025) · Nutrients · doi:10.3390/nu17142382 · Cited by 29
“Driving some of this is the efficacy of the medications, with semaglutide showing ~14% weight loss in clinical trials, and tirzepatide demonstrating ~20% weight loss in clinical trials [78,79].”
Jassil, F. C., Carnemolla, A., Kingett, H., Doyle, J., Kirk, A., Lewis, N., Montagut, G., Marvasti, P., Boniface, D. R., Brown, A. C., et al. (2023) · Obesity · doi:10.1002/oby.23814 · Cited by 38
Relevance and consequence of chronic inflammation for obesity development
Rück, L., Wiegand, S., & Kühnen, P. (2023) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-023-00170-6 · Cited by 35
Obesity: a 100 year perspective
Bray, G. A. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01530-6 · Cited by 44
“This was followed by the even more dramatic weight losses associated with the use of peptides like tirzepatide, which had dual or triple action on GLP-1 receptors, but also GIP (glucose-insulin dependent peptide) and glucagon receptors [86, 87].”
Al-Marzooqi, S. K., Almarzooqi, F., Sadida, H. Q., Jerobin, J., Ahmed, I., Abou‐Samra, A., Fakhro, K. A., Dhawan, P., Bhat, A. A., & Akil, A. A. (2024) · Obesity Reviews · doi:10.1111/obr.13766 · Cited by 37
Hu, Y., Sun, C., Chen, Y., Liu, Y., & Fan, J. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00123 · Cited by 61
Obesity Management in the Primary Prevention of Hepatocellular Carcinoma
Zunica, E. R. M., Heintz, E. C., Axelrod, C. L., & Kirwan, J. P. (2022) · Cancers · doi:10.3390/cancers14164051 · Cited by 32
Lempesis, I. G., Liu, J., & Dalamaga, Μ. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100220 · Cited by 38
Wean, J., Kowalsky, A. H., Laker, R., Will, S., Drucker, D. J., Rhodes, C. J., & Seeley, R. J. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102074 · Cited by 28
“The need to do this is made even more urgent given the confusing fi ndings that drugs that are GLP-1R agonists and GIP antagonists can also produce signi fi cant weight loss in both pre-clinical models and humans [15,48].”
The effect of obesity pharmacotherapy on body composition, including muscle mass
Argyrakopoulou, G., Gitsi, E., Konstantinidou, S. K., & Kokkinos, A. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01533-3 · Cited by 28
“DUAL GLP-1/GIP RECEPTOR AGONISTS Tirzepatide is a once-weekly subcutaneous injectable medication, a dual agonist at both the GIP and GLP-1 receptors approved for both T2DM and obesity (FDA) that has recently entered the obesity pharmacotherapy fi eld [58, 59].”
InfluentialKreiner, F. F., von Scholten, B. J., Kurtzhals, P., & Gough, S. C. L. (2023) · Aging Cell · doi:10.1111/acel.13818 · Cited by 29
The Impact of Obesity on Inflammatory Bowel Disease
Kaazan, P., Seow, W., Yong, S., Heilbronn, L. K., & Segal, J. P. (2023) · Biomedicines · doi:10.3390/biomedicines11123256 · Cited by 36
“Beyond its glycaemic effects, it has a profound effect on body weight [86] and waist-circumference reduction, and it appears to have less side effects than GLP1-RA.”
BackgroundModifiable Cardiometabolic Risk Factors in Survivors of Childhood Cancer
Hammoud, R. A., Mulrooney, D. A., Rhea, I. B., Yu, C. H., Johnson, J. N., Chow, E. J., Ehrhardt, M. J., Hudson, M. M., Ness, K. K., Armstrong, G. T., et al. (2024) · JACC CardioOncology · doi:10.1016/j.jaccao.2023.12.008 · Cited by 35
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Gong, B., Yao, Z., Zhou, C., Wang, W., Sun, L., & Han, J. D. J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116342 · Cited by 29
Reframing prediabetes: A call for better risk stratification and intervention
Kim, S. H. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13786 · Cited by 34
“%) weight loss than semaglutide [90, 91].”
BackgroundTirzepatida: Un Avance Revolucionario en el Tratamiento de la Diabetes Mellitus Tipo 2 y la Obesidad
Chávez, M. (2023) · Revista Veritas de Difusão Cientifica. · doi:10.61616/rvdc.v4i1.39 · Cited by 35
Nutritional Challenges and Treatment After Bariatric Surgery
Moize, V. L., Laferrère, B., & Shapses, S. A. (2024) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061121-101547 · Cited by 40
“The incretin mimetics (e.g., glucagon-like peptide-1 receptor agonists) have shown success with significant weight loss (60, 153).”
Kong, W., Deng, B., Shen, X., John, C. S., Haag, J. G., Sinha, N., Lee, D., Sun, W., Chen, S., Zhang, H., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.10.004 · Cited by 44
Jiang, Y., Zhu, H., & Gong, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16106 · Cited by 36
“37 Clinical trials directly comparing the GLP-1/GIP dual agonist and GLP-1 mono agonist at doses approved for obesity treatment are still missing.”
El-Solh, A., Gould, E., Aibangbee, K. E., Jimerson, T., & Hartling, R. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2437525 · Cited by 34
“In the pivotal SURMOUNT-1 trial, the study enrolled 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, but without type 2 diabetes [66].”
InfluentialPorto, J. R., Lavu, M. S., Hecht, C. J., Kaelber, D. C., Sculco, P. K., Heckmann, N. D., & Kamath, A. F. (2025) · Orthopaedic Journal of Sports Medicine · doi:10.1177/23259671241297157 · Cited by 38
“12,13,23,26,34 Previous studies 28,33 have reported an inherent rate of failure for GLP-1-RAs and poor long-term adherence, with Weiss et al 33 reporting 50.9% adherence at 12 months and 47.4% at 24 months.”
InfluentialOn the causes of obesity and its treatment: The end of the beginning
Friedman, J. M. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.026 · Cited by 34
Cardiovascular, Kidney, Liver, and Metabolic Interactions in Heart Failure: Breaking Down Silos
Lee, C. J. M., Kosyakovsky, L. B., Khan, M. S., Wu, F., Chen, G., Hill, J. A., Ho, J. E., Foo, R., & Zannad, F. M. (2025) · Circulation Research · doi:10.1161/circresaha.125.325602 · Cited by 40
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease
Díaz, L. A., Thiele, M. S., Louvet, A., Lee, B. P., Ajmera, V. H., Tavaglione, F., Hsu, C. L., Huang, D. Q., Pose, E., Bataller, R. A., et al. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01120-5 · Cited by 38
“Other dual or triple agonists, including tirzepatide ( n = 190, NCT04166773) 165 , survodutide ( n = 293, NCT04771273) 166 , pemvidutide ( n = 94, NCT05006885) 167 and retatutride ( n = 98, NCT04881760) 168 , have shown promising results in resolving MASH and reducing body weight, and are…”
Malhotra, A., Grunstein, R., Azarbarzin, A., Sands, S. A., Somers, V. K., Aronne, L. J., Jastreboff, A. M., Lou, J., Chakladar, S., Dunn, J. P., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04071-1 · Cited by 52
“Considerable interest has been accumulated regarding the use of tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, which has previously been shown to improve body weight as well as glucose control 11,12 .”
Self-citationMerola, J. F., Mease, P. J., Kivitz, A., Sattar, N. A., Coates, L. C., Aletaha, D., Kartman, C. E., Fischer, P., Sun, L., Martínez-Osuna, P., et al. (2026) · Arthritis & Rheumatology · doi:10.1002/art.70134 · Cited by 51
“…total cholesterol, tri-glycerides, HbA 1c , and glucose in the IXE + TZP arm are consistent with those reported for TZP in the SURMOUNT trials 31,32 and are additional considerations in the comprehensive treatment of PsA given the high prevalence and burden of over-weight and obesity and…”
Cardiovascular Disease Risk Reduction and Body Mass Index
Samson, R., Ennezat, P. V., Jemtel, T. H. L., & Oparil, S. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01213-5 · Cited by 34
Diabetes in HIV: the Link to Weight Gain
Bailin, S. S., & Koethe, J. R. (2022) · Current HIV/AIDS Reports · doi:10.1007/s11904-022-00642-w · Cited by 35
Sridhar, V. S., Limonte, C. P., Groop, P., Heerspink, H. J. L., Pratley, R. E., Rossing, P. R., Skyler, J. S., & Cherney, D. Z. I. (2023) · Diabetologia · doi:10.1007/s00125-023-06015-1 · Cited by 34
“…applies to dual GLP1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists such as tirzepatide, which have profound effects on glycaemic control and body weight (e.g. 11 kg body weight reduction in the SURPASS-4 trial), preserve the eGFR slope and reduce the UACR [57, 58].”
BackgroundMozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100181 · Cited by 28
Johnson, H., Huang, D., Liu, V., Ammouri, M. A., Jacobs, C., & El-Osta, A. (2025) · Journal of Medical Internet Research · doi:10.2196/69466 · Cited by 27
“Our study, however, underscores the use of tirzepatide in a remote setting, yielding superior weight loss outcomes relative to semaglutide as evidenced in clinical trials [54,55].”
High-quality weight loss in obesity: importance of skeletal muscle
Harper, M.-E., Dent, R. R. M., & McPherson, R. (2025) · Diabetes · doi:10.2337/dbi25-0003 · Cited by 27
“…Treatment Effect in People with Obesity (STEP) 1 (29) and Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1) (30), semaglutide (2.4 mg/week) and tirzepatide (5, 10, and 15 mg/week), respectively, were associated with net losses of 10.1% and 7.9% of initial…”
InfluentialTreating sarcopenic obesity in the era of incretin therapies: perspectives and challenges
Chen, A. S., & Batsis, J. A. (2025) · Diabetes · doi:10.2337/dbi25-0004 · Cited by 32
Identifying obesity subtypes: A review of studies utilising clinical biomarkers and genetic data
Abraham, A., & Yaghootkar, H. (2023) · Diabetic Medicine · doi:10.1111/dme.15226 · Cited by 43
“21 One significant limitation in studies that use biomarkers to identify obesity subtypes is their reliance on BMI.”
BackgroundGoldenberg, R. M., Gilbert, J. D., Manjoo, P., Pedersen, S. D., Woo, V. C., & Lovshin, J. A. (2024) · Obesity Reviews · doi:10.1111/obr.13663 · Cited by 27
“79 Like SURPASS, gastrointestinal outcomes were the primary side effects reported in SURMOUNT-1 and they were mainly transient and mild-to-moderate in severity.”
BackgroundGasbjerg, L. S., Rasmussen, R. S., Dragan, A., Lindquist, P., Melchiorsen, J. U., Stępniewski, T. M., Schiellerup, S. P., Tordrup, E. K., Gadgaard, S., Kizilkaya, H. S., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16478 · Cited by 34
“…Smit et al., 2021) and bone disorders (Gabe et al., 2022), and the incorporation of GIP activity has been suggested to contribute to the impressive glucose-lowering and body weight-reducing effects of the GLP-1 – GIP receptor co-agonist tirzepatide (Frías et al., 2021; Jastreboff et al., 2022).”
Jarade, C., Zolotarova, T., Moiz, A., & Eisenberg, M. J. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102789 · Cited by 32
“51 In the SURMOUNT-1 Trial, once weekly subcutaneous tirze-patide conferred dose-dependent weight reduction up to 20.1% at 72 weeks.”
BackgroundInfluentialWeare-Regales, N., Carr, T. F., Holguín, F., Tibbitt, C. A., & Lockey, R. F. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.09.018 · Cited by 28
Kamrul-Hasan, A. B. M., Alam, M. S., Dutta, D., Sasikanth, T., Aalpona, F. T. Z., & Nagendra, L. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2164 · Cited by 27
“Ten trials involved individuals with T2D [25,27,30-37], while three focused on obese or overweight subjects without diabetes [26,28,29].”
Glycerolipid Cycling in Thermogenesis, Energy Homeostasis, Signaling, and Diseases
Poursharifi, P., Madiraju, S. R. M., Oppong, A. K., Kajimura, S., Nolan, C. J., Blondin, D. P., & Prentki, M. (2025) · Physiological Reviews · doi:10.1152/physrev.00024.2024 · Cited by 31
Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes
Kamalumpundi, V., Shams, E., Tucker, C., Cheng, L., Peterson, J., Thangavel, S., Ofori, O., & Correia, M. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115304 · Cited by 39
The Anti-Inflammatory Effect of Novel Antidiabetic Agents
Theofilis, P., Sagris, Μ., Oikonomou, E. K., Antonopoulos, A. S., Siasos, G., Tsioufis, K., & Tousoulis, D. (2022) · Life · doi:10.3390/life12111829 · Cited by 35
Iannone, A., Natale, P., Palmer, S. C., Nicolucci, A., Rendina, M., Giorgino, F., Laviola, L., Di Leo, A., & Strippoli, G. F. M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15138 · Cited by 27
Koschker, A., Warrings, B., Morbach, C., Seyfried, F., Jung, P., Dischinger, U., Edelmann, F., Herrmann, M. J., Stier, C. K., Frantz, S., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155655 · Cited by 29
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
Stretton, B., Kovoor, J., Bacchi, S., Chang, S., Ngoi, B., Murray, T., Bristow, T. C., Heng, J., Gupta, A., Ovenden, C., et al. (2023) · Internal Medicine Journal · doi:10.1111/imj.16126 · Cited by 26
Gasoyan, H., & Sarwer, D. B. (2022) · Obesity · doi:10.1002/oby.23556 · Cited by 26
“These weight losses were accompanied by a significant reduction in cardiovascular and metabolic risk factors [1, 3].”
BackgroundNew approaches to triglyceride reduction: is there any hope left?
Filtz, A., Parihar, S., Greenberg, G. S., Park, C. M., Scotti, A., Lorenzatti, D., Badimon, J. J., Soffer, D. E., Toth, P. P., Lavie, C. J., et al. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100648 · Cited by 26
“Lastly, Tirze-patide, a novel GLP1-RA and glucagon inhibitory peptide (GIP) agonist, has been associated with a 20.9 % reduction in weight and a 20.3 % reduction in TG levels [96].”
BackgroundInfluentialAn integrative framework to prioritize genes in more than 500 loci associated with body mass index
Hemerich, D., Svenstrup, V., Díez‐Obrero, V., Preuss, M. H., Moscati, A., Hirschhorn, J. N., & Loos, R. J. F. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2024.04.016 · Cited by 29
Añazco, D., & Acosta, A. J. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01599-z · Cited by 43
“Newer GLP-1 receptor agonizts (i.e., semaglutide) and GIP co-agonists (i.e., tirzepatide) have shown signi fi cantly superior weight loss outcomes in comparison to liraglutide [20, 21, 53, 54].”
Rubino, D., Pedersen, S. D., Connery, L. E., Cao, D., Chigutsa, F. B., Stefański, A., Brumm, J. F., Griffin, R. M., & Gerber, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16176 · Cited by 50
Self-citationGarg, S. V., Kaur, G., Renner, D. C., Lanning, M. S., Mason, E., Beatson, C. R., Ciesco, K., & Snell‐Bergeon, J. K. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0481 · Cited by 33
“…and tirzepatide, a dual incretin) and sodium – glucose cotransporter-2 inhibitors (SGLT2is) are approved and commonly used in patients with T2D alone or when patients develop CVD and/or DKD 6 – 8 as recommended by the American Diabetes Association and European Association of Study for Diabetes.”
Yin, Y., Zhang, M., Cao, Q., Lin, L., Lu, J., Bi, Y., & Chen, Y. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70082 · Cited by 35
Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention
Ostrominski, J. W., CHENG, A. Y. Y., Nelson, A. J., Neuen, B. L., Sattar, N. A., Tuttle, K. R., & Vaduganathan, M. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01384-4 · Cited by 35
Kunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 45
“…for obesity), discontinuation mainly due to GI events reached 5.9–16.6% [ 49, 82, 83, 85], while in the SURMOUNT-1–2 and SURPASS-1 trials of tirzepatide, 6.2–7.4% of participants on the highest dose discontinued mainly due to GI side effects, compared with 2.6–3.8% on placebo [42, 87, 170].”
InfluentialKo, A., Chang, Y.-C., Bahar, F., Wang, T. H., Xanthavanij, N., Yu, C.-C., Hsieh, R. J.-L., See, X. Y., Lo, S., Song, J., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-02237 · Cited by 59
Hagan, S., & Nelson, K. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07821-w · Cited by 26
Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond
Dutta, P., Kumar, Y., Babu, A. T., Ravindran, S. G., Salam, A., Rai, B., Baskar, A., Dhawan, A., & Jomy, M. (2023) · Cureus · doi:10.7759/cureus.38379 · Cited by 46
“In terms of obesity, tirzepatide has shown promising results, which can be seen in the SURMOUNT-1 trial [29], where a substantial reduction in body weight was noted.”
BackgroundChichura, K. S., Elfers, C., Salameh, T. S., Kamat, V., Chepurny, O. G., McGivney, A., Milliken, B. T., Holz, G. G., Applebey, S. V., Hayes, M. R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-36178-1 · Cited by 27
Wong, N. D., Karthikeyan, H., & Fan, W. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07488-3 · Cited by 26
Lv, X., Wang, H., Chen, C., Zhao, Y., Li, K., Wang, Y., Wang, L., Fu, S., & Liu, J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s443396 · Cited by 34
“A 72-week clinical study in obese patient has confirmed 25 that once-weekly treatment with 5 mg, 10 mg, or 15 mg TZP results in significant and sustained weight loss.”
BackgroundMoiz, A., Zolotarova, T., Filion, K. B., & Eisenberg, M. J. (2026) · American Journal of Hypertension · doi:10.1093/ajh/hpaf205 · Cited by 26
Abdrabou Abouelmagd, A., Abdelrehim, A. M., Bashir, M. N., Abdelsalam, F., Marey, A., Tanas, Y., Abuklish, D. M., & Belal, M. M. (2025) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2025.2456441 · Cited by 25
Tobaiqy, M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00629-x · Cited by 25
The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
Anala, A. D., Saifudeen, I. S. H., Ibrahim, M., Nanda, M., Naaz, N., & Atkin, S. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144575 · Cited by 39
“Moreover, a trial by the American Diabetes Association supported the previous trial and noted that taking tirzepatide helped lose weight for 9 out of 10 obese adults [115,116].”
ResultTreatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon
Roth, C. L., & Zenno, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1256514 · Cited by 29
“Tirzepatide, a GLP-1 and GIP receptor agonist is an example of a dual agonist that was recently FDA approved for the treatment of adults with type 2 diabetes with its clinical trials showing up to 20% weight loss in participants on the 15 mg dose (114).”
BackgroundMorningstar, M., Kolodziej, A., Ferreira, S., Blumen, T., Brake, R., & Cohen, Y. (2023) · Obesity · doi:10.1002/oby.23902 · Cited by 23
Treatment and practical considerations of diabetic kidney disease
Bilen, Y., Almoushref, A., Alkwatli, K., Osman, O., Mehdi, A., & Sawaf, H. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1264497 · Cited by 30
Storandt, M. H., Tella, S. H., Wieczorek, M. A., Hodge, D. O., Elrod, J. K., Rosenberg, P. S., Jin, Z., & Mahipal, A. (2024) · Cancers · doi:10.3390/cancers16040684 · Cited by 25
“This may be useful in the development of targeted screening measures and allow for the focusing of resources in managing hepatobiliary cancers in the coming years.”
BackgroundOutpatient management of essential hypertension: a review based on the latest clinical guidelines
Moiz, A., Zolotarova, T., & Eisenberg, M. J. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2338242 · Cited by 39
Obesity medications: A narrative review of current and emerging agents
Qi, Q., Cox, A., McNeil, S. E., & Sumithran, P. (2024) · Osteoarthritis and Cartilage Open · doi:10.1016/j.ocarto.2024.100472 · Cited by 42
“In individuals with obesity and glucose intolerance, a greater proportion returned to nor-moglycaemia with tirzepatide treatment, with improved fasting insulin levels, systolic and diastolic blood pressure, fasting lipid pro fi le and physical function [27].”
BackgroundResultInfluentialRethinking weight loss treatments as cardiovascular medicine in obesity, a comprehensive review
Tuccinardi, D., Watanabe, M., Masi, D., Monte, L., Meffe, L. B., Cavallari, I., Nusca, A., Maddaloni, E., Gnessi, L., Napoli, N., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae171 · Cited by 32
A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database
Liu, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1397029 · Cited by 37
Adverse Cardiovascular Outcomes in Patients With Obstructive Sleep Apnea and Obesity
Aminian, A., Wang, L., Jabri, A., Wilson, R. L., Bena, J., Milinovich, A., Jin, J., Heinzinger, C. M., Peña-Orbea, C., Foldvary‐Schaefer, N., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.008 · Cited by 28
Upadhya, B., Brubaker, P. H., Nicklas, B. J., Houston, D. K., Haykowsky, M. J., & Kitzman, D. W. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.06.007 · Cited by 26
The role of bone in energy metabolism: A focus on osteocalcin
Smith, C., Lin, X., Parker, L., Yeap, B. B., Hayes, A., & Levinger, I. (2024) · Bone · doi:10.1016/j.bone.2024.117238 · Cited by 36
Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis
Park, S., Jain, R., & Mirfakhraee, S. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.08.005 · Cited by 26
Nilsson, M. I., Xhuti, D., de Maat, N. M., Hettinga, B. P., & Tarnopolsky, M. A. (2024) · Nutrients · doi:10.3390/nu16244407 · Cited by 43
Nie, Y., Zhang, Y., Liu, B., & Meng, H. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07733-8 · Cited by 30
Self-citationHankosky, E. R., Chinthammit, C., Meeks, A., Huang, A., Ward, J. M., Mojdami, D., & Hunter, T. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16290 · Cited by 39
“17 Similarly, in the current study, 85.8% of individuals on low doses of tirzepatide ( 10 mg) achieved ≥ 5% weight reduction as early as 24 weeks.”
InfluentialVisceral Adiposity and Cardiometabolic Risk: Clinical Insights and Assessment
Shetty, S., Suvarna, R., Bhattacharya, S., & Seetharaman, K. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000984 · Cited by 40
Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions
Karacabeyli, D., & Lacaille, D. V. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01302-0 · Cited by 34
Updated Meta-Analysis Assessing the Cardiovascular Efficacy of Tirzepatide
Patoulias, D., Papadopoulos, C. E., Fragakis, N., & Doumas, M. N. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.07.003 · Cited by 28
Parish, A. J., & Swindell, W. R. (2022) · Aging Cell · doi:10.1111/acel.13733 · Cited by 27
An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal
Enright, C., Thomas, E., & Saxon, D. R. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac195 · Cited by 32
“The recently published SURMOUNT-1 trial examined the efficacy of tirzepatide in producing weight loss in patients with obesity who do not have diabetes [86].”
Management of abdominal wall hernias in patients with severe obesity
Ghanem, O. M., Orenstein, S. B., Lloyd, S. J.-A., Andalib, A., Race, A. J., Burt, H. A., Husain, F. A., Goldblatt, M. I., & Kroh, M. (2023) · Surgical Endoscopy · doi:10.1007/s00464-023-10312-6 · Cited by 28
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.